Guerbet announces marketing authorisation approval of Elucirem™ in the European Union

Guerbet Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom

The marketing authorisation (MA) for Elucirem™ (Gadopiclenol) was granted to Guerbet by the European Commission based on the positive opinion of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) dated 12 October 2023.For the indications approved in the context of this MA, a MRI examination with Elucirem™ requires half the dose of gadolinium compared to that required with existing nonspecific contrast agents, thus answering a major concern of practitioners about gadolinium exposure.[1],[2],[3]Invented, designed and manufactured by Guerbet, Elucirem™ was approved by the FDA in September 2022. It is produced in France and in the USA. It will be marketed by Guerbet in the European Union in the following forms: vials and prefilled syringes.View original content:https://www.prnewswire.co.uk/news-releases/guerbet-announces-marketing-authorisation-approval-of-elucirem-gadopiclenol-in-the-european-union-302011474.html